In Warp Drive Deal, VCs Have A Potential Buyer – And Can Force A Sale
This article was originally published in Start Up
Third Rock launches a computation-heavy discovery firm aimed at natural products, with commitments worth up to $125 million in equity and other funding.
You may also be interested in...
Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
UCSF Spinout Calithera Biosciences Takes $40 Million First Round
The cancer-fighting drug researcher is developing methods of activating caspases, enzymes that induce programmed cell death.
Craig Venter Wants To Extend Your Life (And Own Your Data)
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.